{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:38:49Z","timestamp":1791488329017,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100485"],"award-info":[{"award-number":["82100485"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024QH024"],"award-info":[{"award-number":["ZR2024QH024"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Atherosclerosis is characterized by complex pathological processes, including endothelial dysfunction and inflammation. The underlying pathogenic mechanisms have been well elucidated; however, effective treatments are yet to be validated. Our study explored the novel application of a recognized antiviral agent, remdesivir, focusing on its impact on endothelial activation and atherosclerosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Pharmacological treatment with remdesivir significantly reduced atherosclerotic lesions in the total aorta and decreased VCAM-1 expression in aortic roots of ApoE\u2212\/\u2212\u00a0mice. Remdesivir notably attenuated ox-LDL-induced endothelial cell (EC) activation, monocyte adhesion, and ROS production. In HUVECs, TAL1 interference via siRNA significantly increased TRAF6 protein levels, which was reversed by remdesivir. Remdesivir also reduced both total and K63-linked ubiquitination of TRAF6 in HUVECs. Immunoprecipitation assays revealed diminished co-localization of the two proteins under ox-LDL treatment, but this effect was reversed by remdesivir. Importantly, ectopic adeno-associated virus (AAV)-mediated overexpression of TAL1 reduced atherosclerotic lesions and VCAM-1 expression in the aorta of ApoE\u2212\/\u2212\u00a0mice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In ApoE<jats:sup>\u2013\/\u2013<\/jats:sup> mice fed with a Western diet, remdesivir greatly attenuated atherosclerosis progression. At the cellular level, remdesivir suppressed oxidative stress, THP-1 adhesion, vascular cell adhesion molecule 1, and intercellular adhesion molecule 1 via oxidized low-density lipoprotein in human umbilical vein endothelial cells. T-cell acute lymphoblastic leukemia 1 (TAL1) functions by interacting with the ubiquitin E3 ligase TNF receptor-associated factor 6 (TRAF6) to ubiquitinate TRAF6, inhibiting nuclear factor kappa B activation. Remdesivir also restored the TAL1-TRAF6 interaction and decreased endothelial activation. Endothelial-specific TAL1 over-expression in ApoE<jats:sup>\u2013\/\u2013<\/jats:sup> mice significantly reduced aortic plaque formation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Remdesivir impedes atherosclerosis progression by re-establishing the interaction between TAL1 and TRAF6, diminishing endothelial activation. These findings offer an innovative therapeutic approach for atherosclerosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12967-025-06673-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:50:54Z","timestamp":1751381454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Remdesivir inhibits endothelial activation and atherosclerosis by coupling TAL1 to TRAF6"],"prefix":"10.1186","volume":"23","author":[{"given":"Hanning","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjie","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6277-3466","authenticated-orcid":false,"given":"Chenghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"6673_CR1","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.cell.2022.04.004","volume":"185","author":"J Bj\u00f6rkegren","year":"2022","unstructured":"Bj\u00f6rkegren J, Lusis AJ. Atherosclerosis: recent developments. Cell. 2022;185:1630\u201345.","journal-title":"Cell"},{"key":"6673_CR2","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI115499","volume":"88","author":"JL Witztum","year":"1991","unstructured":"Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785\u201392.","journal-title":"J Clin Invest"},{"key":"6673_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102511","volume":"57","author":"X Luo","year":"2022","unstructured":"Luo X, Weng X, Bao X, et al. A novel anti-atherosclerotic mechanism of quercetin: competitive binding to KEAP1 via Arg483 to inhibit macrophage pyroptosis. Redox Biol. 2022;57: 102511.","journal-title":"Redox Biol"},{"key":"6673_CR4","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1080\/15548627.2023.2213984","volume":"19","author":"Q Li","year":"2023","unstructured":"Li Q, Zhao Y, Guo H, et al. Impaired lipophagy induced-microglial lipid droplets accumulation contributes to the buildup of TREM1 in diabetes-associated cognitive impairment. Autophagy. 2023;19:2639\u201356.","journal-title":"Autophagy"},{"key":"6673_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.66","volume":"4","author":"L Wang","year":"2013","unstructured":"Wang L, Qiu XM, Hao Q, Li DJ. Anti-inflammatory effects of a Chinese herbal medicine in atherosclerosis via estrogen receptor \u03b2 mediating nitric oxide production and NF-\u03baB suppression in endothelial cells. Cell Death Dis. 2013;4: e551.","journal-title":"Cell Death Dis"},{"key":"6673_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P. The changing landscape of atherosclerosis. Nature. 2021;592:524\u201333.","journal-title":"Nature"},{"key":"6673_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0092-8674(00)00126-4","volume":"103","author":"L Deng","year":"2000","unstructured":"Deng L, Wang C, Spencer E, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000;103:351\u201361.","journal-title":"Cell"},{"key":"6673_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/35085597","volume":"412","author":"C Wang","year":"2001","unstructured":"Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412:346\u201351.","journal-title":"Nature"},{"key":"6673_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/imr.12302","volume":"266","author":"MC Walsh","year":"2015","unstructured":"Walsh MC, Lee J, Choi Y. Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system. Immunol Rev. 2015;266:72\u201392.","journal-title":"Immunol Rev"},{"key":"6673_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCRESAHA.118.313143","volume":"123","author":"Y Lv","year":"2018","unstructured":"Lv Y, Kim K, Sheng Y, et al. YAP controls endothelial activation and vascular inflammation through TRAF6. Circ Res. 2018;123:43\u201356.","journal-title":"Circ Res"},{"key":"6673_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1406","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhu Z, Cao Y, et al. Rnd3 suppresses endothelial cell pyroptosis in atherosclerosis through regulation of ubiquitination of TRAF6. Clin Transl Med. 2023;13: e1406.","journal-title":"Clin Transl Med"},{"key":"6673_CR12","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/eurheartj\/ehaa770","volume":"42","author":"A Akhmedov","year":"2021","unstructured":"Akhmedov A, Sawamura T, Chen CH, Kraler S, Vdovenko D, L\u00fcscher TF. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease. Eur Heart J. 2021;42:1797\u2013807. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa770.","journal-title":"Eur Heart J"},{"key":"6673_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1161\/ATVBAHA.120.315421","volume":"41","author":"J Barreto","year":"2021","unstructured":"Barreto J, Karathanasis SK, Remaley A, Sposito AC. Role of LOX-1 (Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1) as a cardiovascular risk predictor: mechanistic insight and potential clinical use. Arterioscler Thromb Vasc Biol. 2021;41:153\u201366. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315421.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6673_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1527-3466.2007.00009.x","volume":"25","author":"XP Chen","year":"2007","unstructured":"Chen XP, Zhang TT, Du GH. Lectin-like oxidized low-density lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis. Cardiovasc Drug Rev. 2007;25:146\u201361. https:\/\/doi.org\/10.1111\/j.1527-3466.2007.00009.x.","journal-title":"Cardiovasc Drug Rev"},{"key":"6673_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","volume":"12","author":"G Kokic","year":"2021","unstructured":"Kokic G, Hillen HS, Tegunov D, et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun. 2021;12:279.","journal-title":"Nat Commun"},{"key":"6673_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048\u201357.","journal-title":"JAMA"},{"key":"6673_CR17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","volume":"80","author":"YN Lamb","year":"2020","unstructured":"Lamb YN. Remdesivir: first approval. Drugs. 2020;80:1355\u201363.","journal-title":"Drugs"},{"key":"6673_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.bbrc.2020.03.034","volume":"526","author":"YN Li","year":"2020","unstructured":"Li YN, Su Y. Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING. Biochem Biophys Res Commun. 2020;526:381\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"6673_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652446","volume":"12","author":"L Yin","year":"2021","unstructured":"Yin L, Zhao H, Zhang H, et al. Remdesivir alleviates acute kidney injury by inhibiting the activation of NLRP3 inflammasome. Front Immunol. 2021;12: 652446.","journal-title":"Front Immunol"},{"key":"6673_CR20","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3324\/haematol.2022.281583","volume":"108","author":"C Smith","year":"2023","unstructured":"Smith C, Goyal A, Weichenhan D, et al. TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3\u2019 neo-enhancer. Haematologica. 2023;108:1259\u201371.","journal-title":"Haematologica"},{"key":"6673_CR21","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2016-12-754051","volume":"129","author":"C Porcher","year":"2017","unstructured":"Porcher C, Chagraoui H, Kristiansen MS. SCL\/TAL1: a multifaceted regulator from blood development to disease. Blood. 2017;129:2051\u201360.","journal-title":"Blood"},{"key":"6673_CR22","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1242\/dev.00875","volume":"130","author":"M Gering","year":"2003","unstructured":"Gering M, Yamada Y, Rabbitts TH, Patient RK. Lmo2 and Scl\/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1. Development. 2003;130:6187\u201399.","journal-title":"Development"},{"key":"6673_CR23","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1161\/CIRCULATIONAHA.113.007727","volume":"130","author":"JK Han","year":"2014","unstructured":"Han JK, Chang SH, Cho HJ, et al. Direct conversion of adult skin fibroblasts to endothelial cells by defined factors. Circulation. 2014;130:1168\u201378.","journal-title":"Circulation"},{"key":"6673_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110945","volume":"39","author":"B Dobosh","year":"2022","unstructured":"Dobosh B, Zandi K, Giraldo DM, et al. Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes. Cell Rep. 2022;39: 110945.","journal-title":"Cell Rep"},{"key":"6673_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","volume":"593","author":"S Yuan","year":"2021","unstructured":"Yuan S, Yin X, Meng X, et al. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature. 2021;593:418\u201323.","journal-title":"Nature"},{"key":"6673_CR26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1124\/pharmrev.120.000096","volume":"73","author":"S Xu","year":"2021","unstructured":"Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73:924\u201367.","journal-title":"Pharmacol Rev"},{"key":"6673_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1194\/jlr.M800474-JLR200","volume":"50","author":"OL Francone","year":"2009","unstructured":"Francone OL, Tu M, Royer LJ, et al. The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding. J Lipid Res. 2009;50:546\u201355.","journal-title":"J Lipid Res"},{"key":"6673_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/cvr\/cvp177","volume":"84","author":"K Sugimoto","year":"2009","unstructured":"Sugimoto K, Ishibashi T, Sawamura T, et al. LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovasc Res. 2009;84:127\u201336.","journal-title":"Cardiovasc Res"},{"key":"6673_CR29","doi-asserted-by":"publisher","first-page":"11267","DOI":"10.1038\/ncomms11267","volume":"7","author":"YX Ji","year":"2016","unstructured":"Ji YX, Zhang P, Zhang XJ, et al. The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling. Nat Commun. 2016;7:11267.","journal-title":"Nat Commun"},{"key":"6673_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13046-023-02861-4","volume":"42","author":"Y Jin","year":"2023","unstructured":"Jin Y, Cai Q, Wang L, et al. Paracrine activin B-NF-\u03baB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming. J Exp Clin Cancer Res. 2023;42:269.","journal-title":"J Exp Clin Cancer Res"},{"key":"6673_CR31","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1021\/jacs.1c01045","volume":"143","author":"AM Patel","year":"2021","unstructured":"Patel AM, Marsh E. The antiviral enzyme, viperin, activates protein ubiquitination by the E3 ubiquitin ligase, TRAF6. J Am Chem Soc. 2021;143:4910\u20134.","journal-title":"J Am Chem Soc"},{"key":"6673_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1610","volume":"369","author":"RE Ferner","year":"2020","unstructured":"Ferner RE, Aronson JK. Remdesivir in covid-19. BMJ. 2020;369: m1610.","journal-title":"BMJ"},{"key":"6673_CR33","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/eurheartj\/ehad304","volume":"44","author":"C Weber","year":"2023","unstructured":"Weber C, Habenicht A, von Hundelshausen P. Novel mechanisms and therapeutic targets in atherosclerosis: inflammation and beyond. Eur Heart J. 2023;44:2672\u201381.","journal-title":"Eur Heart J"},{"key":"6673_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.matbio.2020.10.003","volume":"95","author":"H Lv","year":"2021","unstructured":"Lv H, Wang H, Quan M, Zhang C, Fu Y, Zhang L, Lin C, Liu X, Yi X, Chen J, Wang X, Cheng T, Ai D, Kong W, Zhu Y. Cartilage oligomeric matrix protein fine-tunes disturbed flow-induced endothelial activation and atherogenesis. Matrix Biol. 2021;95:32\u201351. https:\/\/doi.org\/10.1016\/j.matbio.2020.10.003.","journal-title":"Matrix Biol"},{"key":"6673_CR35","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.120.316857","volume":"127","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhou T, Chen Z, et al. Coupling of integrin \u03b15 to annexin A2 by flow drives endothelial activation. Circ Res. 2020;127:1074\u201390.","journal-title":"Circ Res"},{"key":"6673_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2022.03.011","volume":"347","author":"J Chen","year":"2022","unstructured":"Chen J, Zhuang R, Cheng HS, Jamaiyar A, Assa C, McCoy M, et al. Isolation and culture of murine aortic cells and RNA isolation of aortic intima and media: rapid and optimized approaches for atherosclerosis research. Atherosclerosis. 2022;347:39\u201346.","journal-title":"Atherosclerosis"},{"issue":"1","key":"6673_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4196\/kjpp.2015.19.1.35","volume":"19","author":"S Choi","year":"2015","unstructured":"Choi S, Kim JA, Kim KC, Suh SH. Isolation and in vitro culture of vascular endothelial cells from mice. Korean J Physiol Pharmacol. 2015;19(1):35\u201342.","journal-title":"Korean J Physiol Pharmacol"},{"key":"6673_CR38","first-page":"52965","volume":"118","author":"JM Wang","year":"2016","unstructured":"Wang JM, Chen AF, Zhang K. Isolation and primary culture of mouse aortic endothelial cells. J Vis Exp. 2016;118:52965.","journal-title":"J Vis Exp"},{"key":"6673_CR39","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1161\/CIRCRESAHA.122.321322","volume":"131","author":"M Quan","year":"2022","unstructured":"Quan M, Lv H, Liu Z, et al. MST1 suppresses disturbed flow induced atherosclerosis. Circ Res. 2022;131:748\u201364.","journal-title":"Circ Res"},{"key":"6673_CR40","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI122440","volume":"129","author":"B Li","year":"2019","unstructured":"Li B, He J, Lv H, et al. c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow. J Clin Invest. 2019;129:1167\u201379.","journal-title":"J Clin Invest"},{"issue":"12","key":"6673_CR41","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/cvr\/cvab012","volume":"117","author":"A Remes","year":"2021","unstructured":"Remes A, Arif R, Franz M, Jungmann A, Zaradzki M, Puehler T, et al. AAV-mediated AP-1 decoy oligonucleotide expression inhibits aortic elastolysis in a mouse model of Marfan syndrome. Cardiovasc Res. 2021;117(12):2459\u201373.","journal-title":"Cardiovasc Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06673-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06673-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06673-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:50:55Z","timestamp":1751381455000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06673-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6673"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06673-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"8 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Protection and Utilization Committee of Ji Ning First People\u2019s Hospital (No. JNRM-2023-DW-036). Informed consent was obtained from all individual participants included in the study. All human experiments were approved by the Medical Ethics Committee of Ji Ning First People\u2019s Hospital (KYLL-202404-025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0A and C.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"719"}}